# Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

> **NCT04300881** · PHASE2 · TERMINATED · sponsor: **Wagner Macula & Retina Center** · enrollment: 2 (actual)

## Conditions studied

- Vitreomacular Traction
- Subretinal Edema

## Interventions

- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT04300881
- **Lead sponsor:** Wagner Macula & Retina Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-04
- **Primary completion:** 2021-01-05
- **Final completion:** 2021-01-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Enrollment
- **Last updated:** 2021-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04300881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04300881, "Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT04300881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*